D. Boral Capital Initiates Coverage on Context Therapeutics (NASDAQ:CNTX)

D. Boral Capital began coverage on shares of Context Therapeutics (NASDAQ:CNTX) in a report issued on Monday, Marketbeat reports. The firm issued a buy rating and a $9.00 price target on the stock.

Separately, HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of Context Therapeutics in a research report on Monday, September 23rd. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $6.80.

Context Therapeutics Price Performance

Context Therapeutics stock opened at $1.50 on Monday. The stock has a market capitalization of $112.50 million, a PE ratio of -1.65 and a beta of 2.25. The business has a 50 day simple moving average of $1.96 and a 200-day simple moving average of $2.07. Context Therapeutics has a 12 month low of $0.77 and a 12 month high of $2.75.

Context Therapeutics (NASDAQ:CNTX) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.11). On average, equities research analysts anticipate that Context Therapeutics will post -0.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Context Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Y Intercept Hong Kong Ltd acquired a new stake in shares of Context Therapeutics in the third quarter valued at about $89,000. Renaissance Technologies LLC grew its stake in Context Therapeutics by 63.4% during the 2nd quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock valued at $131,000 after acquiring an additional 25,300 shares in the last quarter. State Street Corp raised its holdings in Context Therapeutics by 21.5% in the 3rd quarter. State Street Corp now owns 111,907 shares of the company’s stock valued at $219,000 after acquiring an additional 19,800 shares during the last quarter. Opaleye Management Inc. lifted its stake in Context Therapeutics by 13.7% in the 1st quarter. Opaleye Management Inc. now owns 1,108,357 shares of the company’s stock worth $1,530,000 after purchasing an additional 133,357 shares in the last quarter. Finally, Affinity Asset Advisors LLC boosted its holdings in shares of Context Therapeutics by 392.4% during the 2nd quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock worth $3,246,000 after purchasing an additional 1,290,323 shares during the last quarter. Institutional investors and hedge funds own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.